Search results
$19.3 billion
- Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12 Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery in 2023 and expecting additional sales from key markets
People also ask
What is Moderna doing in FY 2022?
How did Moderna's Q1 FY 2022 earnings beat analysts' expectations?
Why did Moderna spend so much in 2022?
How much cash does Moderna have on its balance sheet?
Was 2022 a good year for Moderna?
Did Moderna announce a $3 billion stock purchase program?
Feb 23, 2023 · Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12. Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery in 2023 and expecting additional sales from key markets.
- Moderna Reports Second Quarter 2022 Financial Results and ...
Second quarter 2022 revenues of $4.7 billion; GAAP net...
- Moderna Reports Second Quarter 2022 Financial Results and ...
Aug 3, 2022 · Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24. Company reiterates advance purchase agreements for expected delivery in 2022 of approximately $21 billion. Company announces new $3 billion share repurchase plan
View or download the webcast for Moderna's quarterly financial results press releases for 2021 and 2022.
Jan 9, 2023 · Ahead of Moderna CEO Stéphane Bancel's state-of-the-company address at the J.P. Morgan Healthcare Conference, the company released key financial figures, including vax sales of $18.4 billion in...
- Kevin Dunleavy
- Overview
- Moderna (MRN Financial Results: Analysis
- MRNA Vaccine Developments
Moderna's EPS and revenue crushed analysts' consensus estimates.
Revenue was driven by sales of Moderna's vaccine against COVID-19.
that far surpassed analyst expectations.
came in positive for the fifth straight quarter in a row, beating estimates by a wide margin. Revenue also came in well above analyst expectations.
revenue of $6.1 billion, which more than tripled from the year-ago quarter, was driven by sales of its COVID-19 vaccine.
The company's shares rose more than 6% in
Over the past year, Moderna's shares have provided a
of -21.2%, below the S&P 500's total return of -0.9%.
Moderna's primary source of revenue is currently through sales of its COVID-19 vaccine, which accounted for about 98% of total revenue. The other 2% comprised grant revenue and collaboration revenue.
Moderna's vaccine received full approval for use in individuals aged 18 years or older from the
U.S. Food and Drug Administration (FDA)
in late January 2022. It was just the second COVID-19 vaccine to receive full approval from the FDA, after the vaccine created by Pfizer Inc. (
) and BioNTech SE (
) was approved in August 2021.
Aug 3, 2022 · MRNA beat earnings and revenue estimates. By. Becca Schimmel. Published August 03, 2022. 11:31 AM EDT. Key Takeaways. Moderna sees continuing strong demand for its COVID-19 vaccine. The company has...
Mar 3, 2022 · Key Points. Pfizer expects $32 billion in Covid vaccine sales for 2022, while Moderna is forecasting at least $19 billion in sales. Analysts are debating what future vaccine demand will look...
